Introduction
Docetaxel is a widely used antitumor drug that is semi-synthesized from 10-deacetylbaccatin III, an inactive taxoid precursor prepared from needles of the European yew, Taxus baccata. 1 It has been used to treat a broad spectrum of solid tumors such as advanced ovarian cancer, non-small-cell lung cancer, locally advanced or metastatic breast cancer, and androgen-independent prostate cancer. [2] [3] [4] Docetaxel belongs to the taxane family that can promote assembly of free tubulin into microtubules and stabilize them by binding to tubulin to inhibit disassembly of microtubules. 5, 6 Docetaxel suppresses tumor cell growth in two different modes: at high concentration, docetaxel induces G2/M cell cycle arrest and apoptosis, whereas a very low level of docetaxel causes aberrant mitosis followed by necrosis. 7, 8 Although docetaxel has many advantages in cancer therapy, it can cause serious side effects, such as neutropenia, myelosuppression, anemia, and hypersensitivity reaction, which limit its clinical applications. [9] [10] [11] Some of these side effects are simply induced by The authors' previous work showed that docetaxel-loaded solid lipid nanoparticles (DSNs) have many advantages compared with other nanoformulations, including easier preparation, better stability, component materials safety, and controlled release. 29, 30 The authors have performed systemic analysis of DSN toxicity, including acute toxicity, irritation, allergenicity, and long-term toxicity, using different animal models. 29 Compared with commercially available formulations of docetaxel (Taxotere ® [TAX] ), DSNs have lowered hemotoxicity, hepatotoxicity, and myelotoxicity. 29 In addition, DSNs increase the maximum tolerated dose of TAX, reduce the inherent toxicity, and prevent the associated anaphylaxis induced by polysorbate 80. 29 Breast cancer is one of the most common malignant tumors and the most significant cause of mortality among women around the world. 31, 32 For early, high-risk, and metastatic breast cancer patients, docetaxel is one of the most effective drugs for adjuvant therapy. 4, 33 In the present work, the antibreast cancer activity and toxicity of newly formulated DSNs were evaluated both in vitro and in vivo. Moreover, the potential molecular mechanisms in tumor suppression and toxicity reduction were investigated by gene expression profiles and different cellular and molecular approaches.
Materials and methods Drugs
Docetaxel was purchased from Shenzhen Main Luck Pharmaceuticals Inc., (Shenzhen, People's Republic of China). DSNs and blank solid lipid nanoparticles (BSNs) were prepared at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, People's Republic of China).
Preparation and characterization of DsNs
DSNs were prepared by the high-pressure homogenization method, as described previously. 29 Briefly, a mixture of docetaxel/soybean lecithin/trimyristin (1:5:15, w/w) was dissolved in ethanol, added to preheated water (65°C) under agitation, and sonicated to form the oil-in-water emulsions. Then, the emulsions were homogenized with a high-pressure homogenizer (EmulsiFlex-C3; Avestin, Inc., Ottawa, ON, Canada) for three cycles at 20,000 psi to form the DSNs. The BSNs were prepared using the same procedure. Thereafter, the DSN suspension was lyophilized and stored at 4°C for further measurements. The size distribution and ζ potential values of DSNs were measured by dynamic light scattering (Nicomp 380 ZLS; Particle Sizing Systems, Port Richey, FL, USA). The morphology of DSNs was observed by a transmission electron microscope (CM12; Philips NV, Amsterdam, the Netherlands). The encapsulation efficiency of docetaxel in the DSNs was determined by high-performance liquid chromatography quantification, as described previously ( Agilent 1100; Agilent Technologies, Santa Clara, CA, USA). 29 cell cytotoxicity assay Cells were obtained from American Type Culture Collection (Rockville, MD, USA). The cytotoxicity of TAX, DSNs, and BSNs was evaluated by Cell Counting Kit-8 system (Dojindo Laboratory, Kumamoto, Japan). Cells were seeded into 96-well plates at the density of 5×10 3 cells in 100 µL complete Dulbecco's Modified Eagle Medium (DMEM) per well. After being cultured for 24 hours, cells were treated with different doses of DSNs (0-100 nM) or equivalent TAX for 24 hours, 48 hours, and 72 hours. Equivalent BSNs were used as the control. After cells were treated for the indicated time, Cell Counting Kit-8 was added and incubated for 1 hour at 37°C. Absorbance was measured at 450 nM with a SpectraMax ® M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA). The cell viability was calculated and shown as the mean ± standard error of triplicate experiments.
In vivo tumor suppression test
The tumor suppression effects of DSNs and TAX were investigated with tumor-bearing female BALB/c nude mice in the JOINN Laboratories (Beijing, People's Republic of China). BALB/c nude mice were purchased from Vital River Laboratories (Beijing, People's Republic of China). Mice were subcutaneously injected with MCF-7 cells. After 3 weeks, the tumor-bearing mice were sacrificed and the tumor tissues were isolated and cut into pieces of about 2 mm 3 under aseptic conditions. Around 4-5 week-old mice were subcutaneously inoculated with tumor tissue in the right flank. Tumors were allowed to grow to about 50-100 mm 3 . Mice bearing a similar tumor volume were chosen and randomly divided into four groups, with six mice in each group. Mice from different groups were treated with 10 mg/kg of TAX, DSNs, equivalent BSNs, or glucose (GLU) separately by tail vein injection every 4 days. Body weight and tumor size were measured every 3 days. Mice were sacrificed on Day 12 and tumor tissues were isolated and frozen in liquid nitrogen immediately for future studies. Tumor volume was calculated as one-half of the product of the three orthogonal diameters. Relative tumor volume (RTV) was calculated as the volume on a specific day after drug treatment divided by the initial volume before treatment.
Microarray assay and data analysis
Total RNA was isolated from frozen tumor samples and hybridized to Affymetrix Human Genome U133 Plus 2.0 Array by CapitalBio Corporation (Beijing, People's Republic of China) according to the Affymetrix GeneChip ® Expression Analysis Technical Manual. The GeneChip contains 47,000 transcripts corresponding to 38,500 confirmed human genes. The expression raw data was preprocessed using robust multichip analysis with quantile normalization and custom CDF file hgu133plus2hsentrezgcdf, version 17.1.0. 34 A limma linear model with empirical Bayes moderation was applied for differentially expressed gene calling. 35 The adjusted P-value for significance cutoff was 0.05, and the fold change cutoff was 1.5. Differentially expressed genes were cluster ordered on the basis of their correlations (average linkage, Spearman's rank correlation), with hierarchical clustering. Gene enrichment analysis of annotation terms was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) functional annotation program. 36 The microarray data from this study have been submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm. nih.gov/geo/) under accession number GSE54091.
Quantitative polymerase chain reaction (qPcr)
The qPCR was performed with iQ ™ 5 Multicolor RealTime PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's recommendations. The total RNA used was the same as that used in the microarray assay and purified with RNeasy Plus Mini Kit (Qiagen NV, Venlo, the Netherlands). Purified RNA was reverse transcribed into complementary DNA by using an Oligo(dT) 15 Primer (Promega Corporation, Fitchburg, WI, USA) and M-MLV Reverse Transcriptase (Promega) following the manufacturer's instructions. The qPCR was performed with iQ SYBR ® Green Supermix (Bio-Rad) with standard protocol. Sequences of the primers were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/ index.html) and OligoArchitect ™ Online tools v3.0 (SigmaAldrich Co., St Louis, MO, USA), and the optimal primer pairs were verified by regular PCR. The amplification factor was calculated by the comparative threshold cycle method. β-actin was used as the internal control.
Immunoblotting
Proteins were detected by standard immunoblotting protocol. Frozen tumor tissues were homogenized with a mortar and pestle in liquid nitrogen, then the powder was lysed with radioimmunoprecipitation assay buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM sodium orthovanadate, 
Results

Preparation and characterization of DsNs
DSNs were prepared with a conventional high-pressure homogenization method. The DSNs were round and uniform as observed by transmission electron microscopy ( Figure S1 ). The mean diameter of the DSNs was 37.17±0.35 nm and the polydispersity index was 0.258±0.030, which was in accordance with the transmission electron microscope measurements. In addition, the ζ potential of the DSNs was -28.1±3.53 MV. The encapsulation efficiency of DSNs was 91.77%±1.75%, which implicates the high encapsulation of docetaxel in the solid lipid nanoparticles.
cytotoxicity of DsNs and TaX in McF-7 cells
Previous studies have shown that TAX can suppress the growth of MCF-7 breast cancer cells, and have used MCF-7 cells to study its mechanisms. 7, 8 To explore whether DSNs have a similar tumor suppression effect to TAX, MCF-7 cells were treated with different doses of DSNs and TAX as well as BSNs for 24, 48, and 72 hours, respectively. Complete DMEM with 10% FBS was used as the control. For each drug used, different doses from 1 nM-100 nM were tested. After treatment for the indicated duration and concentration, cell viability was explored by Cell Counting Kit-8 assay. 37 Cell growth was greatly suppressed by DSNs and TAX in a dose-and time-dependent manner, although BSNs did not show an obvious growth suppression effect compared with the DMEM control at every dose and time point tested ( Figure 1 ). The cytotoxicity of DSNs was compared with TAX at each dose at indicated time points. After treatment for 24 hours, the percentage of viable cells in the DSN-or TAX-treated group showed no significant difference at every dose used ( Figure 1A ; P0.05). However, DSNs showed significant lower cytotoxicity in MCF-7 cells compared
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Tumor suppression and toxicity of DsNs with TAX at doses of 10 nM after 48-hours of treatment and 2 nM after 72-hours of treatment, respectively (Figure 1B and C; P0.05). These data suggest that both DSNs and TAX strongly suppress the growth of MCF-7 breast cancer cells. The data also suggests that the suppression effect of DSNs is not from the nanoparticle carrier, as BSNs do not show any suppression effect in vitro.
apoptosis induced by DsNs and TaX in McF-7 cells
Most antitumor drugs can suppress tumor cell growth by inducing apoptosis. To explore whether DSNs and TAX also induced apoptosis, MCF-7 cells were stained with Annexin V-fluorescein isothiocyanate and propidium iodide after treatment with DSNs and TAX. Cells were incubated with 1 nM, 5 nM, 10 nM, 50 nM, and 100 nM DSNs and TAX for 24 and 48 hours, respectively. Then, apoptotic cells were detected by flow cytometry. Results from three independent experiments showed that both DSNs and TAX induced apoptosis, including both early apoptosis and late apoptosis in a dose-and time-dependent manner, while a very low level of apoptosis was detected in the control samples ( Figure 1 
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Yuan et al at the same dose and time points except for 24-hour treatment with the 5 nM dose (Figure 1 ; P0.05). When MCF-7 cells were treated with 5 nM DSNs and TAX for 24 hours, the percentage of apoptotic cells was 29.6%±1.5% versus 20.8%±1.3%, respectively, which shows a significant difference (Figure 1D and E; P0.05). DSN-and TAX-induced apoptosis was also demonstrated by morphological changes of treated cells detected under a microscope, and these results were consistent with that of flow cytometry ( Figure S2 ). All these data suggest that both DSNs and TAX induce apoptosis in MCF-7 cells, and DSNs are more efficient compared with TAX when treated for 24 hours at the 5 nM dose after 24-hour treatment.
Cell cycle profiles after DSN and TAX treatment
As docetaxel causes aberrant mitosis and impairs proliferation of tumor cells by stabilizing the microtubules, it was further tested whether DSNs and TAX induce cell cycle arrest. Cell cycle profiles were analyzed by flow cytometry after propidium iodide staining. Consistent with previous results, 7, 8 most cells were arrested at the G2/M phase after TAX treatment in a dose-dependent manner (Figure 2 ). The percentage of G2/M phase cells was as high as 82.11%±1.76% when cells were treated with 100 nM TAX for 24 hours compared with 23.55%±3.93% in non-treated control samples (Figure 2A and B 
Tumor suppression of DsNs and TaX in vivo
To explore whether DSNs can be used to treat tumors in vivo, the tumor suppression effect of DSNs and TAX was investigated in tumor transplantation nude mice. BALB/c nude mice were subcutaneously injected with MCF-7 cells and tumors were formed after about 3 weeks. The tumor tissue was isolated and cut into almost equal-sized pieces under aseptic conditions and subcutaneously inoculated into the axilla of nude mice. Tumor-bearing mice were randomly divided into four groups, with six mice in each group. The mice in each group were treated with GLU, BSNs, TAX, or DSNs separately by tail vein injection. The drug dose was 10 mg/kg animal weight and the injection was performed every 4 days. Body weight and tumor size were measured every 3 days until the mice were sacrificed. In the GLUtreated group, the mice gained body weight regularly and the mean tumor volume increased gradually (Figure 3) . On Day 11, the day before the mice were sacrificed, the mean tumor volume in the GLU group was 9.45-fold greater than before treatment, and RTV was 9.45±3.43 ( Figure 3B ; Table 1 ). In the BSN-treated group, the mice also gained body weight regularly and the RTV on Day 11 was 8.85±2.40; both body weight and RTV were not significantly different compared with the GLU-treated group ( Figure 3 ; Table 1 ; P0.05). These data suggest that BSNs do not cause any potential toxicity in tumor-bearing mice and have no tumor suppression effect by itself. Compared with the control groups, the body weight of TAX-and DSN-treated mice decreased gradually, while RTV was reduced significantly in both groups (0.76±0.34 in the TAX-treated group and 1.37±1.05 in the DSN-treated group) ( Figure 3 ; Table 1 ; P0.01); however, (Table S1 ). As a safe and simple component material, BSNs showed no significant difference in the gene transcription profile compared with GLU, although the cutoff was as low as adjusted P0.05 and fold change 1.5 (data not shown). Genes upregulated by TAX and DSNs are mainly involved in secrete and signal peptide coding, negative regulation of cell proliferation, and regulation of cell death ( Figure 4A , Group 1; Table S1 ), and genes downregulated by TAX and DSNs are mainly involved in DNA replication, DNA damage response, and the cell cycle process ( Figure 4A , Group 2; Table S1 ). Compared with BSNs and GLU treatment, TAX induced 135 upregulated genes and 489 downregulated genes, DSNs induced 53 upregulated genes and 106 downregulated genes ( Figure 4B ; Table S1 ). Genes up-or downregulated by DSN treatment mostly overlapped with the TAX-treated group, with 49 upregulated genes and 98 downregulated genes in common ( Figure 4B ; Table S1 ). As TAX and DSNs have the same functions to induce apoptosis, arrest cell cycle at the G2/M stage, and suppress tumor growth in vivo, the microarray results provide further evidence that TAX and DSNs are working similarly both towards intrinsic mechanisms and antitumor therapy. The microarray data from this study have been submitted to the NCBI Gene Expression Omnibus under accession number GSE54091.
To verify the microarray assay results, qPCR experiments were performed. Twenty-seven potential genes were investigated (Table S2 ). The qPCR results showed that 21 genes were expressed at the same level as detected by microarray assay (Table 2; Figure 5 ; Figure S3 ), and these genes have functions in the cell cycle, apoptosis, DNA damage response, and proliferation -with the only exception being SMC1A, which is involved in the cell cycle. The five genes that were inconsistent do not have functions in the cell cycle, apoptosis, DNA damage, or proliferation.
Protein expression regulated by TaX and DsNs
This study has shown that DSNs and TAX can influence cell proliferation, apoptosis, and the cell cycle. To investigate whether the protein expression of genes involved in these functions was also altered after DSN and TAX treatment, the protein expression of 18 genes that were verified by qPCR and involved in proliferation, apoptosis, the cell cycle, and DNA damage response were detected. Proteins were extracted from the same tumor tissue used in the messenger RNA experiments and detected with standard protocol. Compared with the GLU-treated group, the BSN-treated group did not cause any significant difference in protein expression level, which is consistent with the transcription level ( Figure 5 ; Figure S4 ). In the TAX-and DSN-treated groups, 14 genes showed the same trend of protein expression as that of transcription. Surprisingly, four proteins showed the opposite trend to transcription ( Figure 5 ; Figure S4 ). Moreover, one obvious difference between the TAX-and DSN-treated groups was observed. Although these 14 genes were expressed at a similar transcription level in both groups, 12 of them had different protein expression compared with transcription. These genes were: ERBB3, FAM172A, MKI67, and NASP -involved in proliferation regulation; E2F8, CCNG2, MCM6, and OIP5 -involved in cell cycle regulation; MRE11, ATRX, and MYB -involved in DNA damage response; and IGFBP3 -involved in apoptosis ( Figure 5 ; Figure S4 ). Only SOD2 and PDCD4 had an equal protein expression and transcription level ( Figure 5 ). SOD2 and PDCD4 have multiple functions in double-strand break repair, cell apoptosis, proliferation, and regulation of progression through the cell cycle. These data suggest that DSNs not only induce gene expression at the transcription level like TAX but also influence protein expression, and some proteins were expressed at a different level. The different expression of these proteins might be the reason that DSNs and TAX show different anticancer activity and reduced toxicity, which needs further investigation.
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Myelosuppression of TaX and DsNs
TAX causes serious side effects when used clinically, and myelosuppression is one of the major side effects. In the authors' previous study, it was shown that the proliferation of bone marrow cells and the number of granulocytes were significantly reduced by TAX treatment in beagle dogs, whereas DSNs reduced TAX-induced bone marrow cytotoxicity by increasing proliferation of the bone marrow cells. 29 Besides the increased proliferation of bone marrow cells, it was expected that the reduced cytotoxicity could be due to an increased number of mature cells from bone marrow primogenitor cells. To investigate this possibility, hematopoietic CFC assays were performed with primary mouse bone marrow cells in methylcellulose semi-solid medium containing DSNs or TAX to evaluate their myelosuppression toxicity. 38 Primary mouse bone marrow cells were isolated from the tibias of 7-week-old BALB/C mice 38 and cultured in methylcellulose-based medium. The cells were then treated with 3 nM or 6 nM DSNs or TAX for 9 days, and CFUs, including erythroid progenitors (BFU-Es) ( 
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Yuan et al both cell types), and CFU-GEMMs (which tend to produce large colonies of 500 cells containing erythroblasts and recognizable cells of at least two other lineages), were counted. Compared with mock-treated cells, the number of CFU-GMs did not change significantly in the 3 nM BSN-, DSN-, and TAX-treated groups ( Figure 6B ; 88.33±4.51 in the GLUtreated control group, 78±7.81 in the BSN-treated group, 78.33±5.13 in the DSN-treated group, and 73.33±9.29 in the TAX-treated group), whereas 6 nM TAX greatly reduced the number of CFU-GMs ( Figure 6B ; 25.67±7.09 in the TAXtreated group). Similar to CFU-GMs, the number of BFU-Es did not significantly change in the 3 nM BSN-, DSN-, and TAX-treated groups (Figure 6C ; 9.67±1.15 in the GLUtreated control group, 9.33±4.04 in the BSN-treated group, 9±1.73 in the DSN-treated group, and 3.67±3.79 in the TAX-treated group), whereas 6 nM TAX greatly reduced the number of BFU-Es ( Figure 6C ; 0 in the TAX-treated group). When treated with 6 nM DSNs, hematopoietic recovery was clearly seen, indicated by an increased number of myeloid progenitor cells (CFU-GMs) and BFU-Es. The CFU-GMs recovered to almost the same level as the control (Figure 6B ; 71±5.57 in the DSN-treated group), and the BFU-Es -though not to the same level as the control -recovered significantly compared with TAX ( Figure 6C; 1.33±0 .58 in the DSNtreated group and 0 in the TAX-treated group; P0.05). Recovery of CFU-GEMMs could not be clearly seen in the DSN-treated group ( Figure 6D ; 4.67±1.53 in the GLU-treated control group, 1.33±1.53 in the 3 nM BSN-treated group, 1.00±1.00 in the 3 nM DSN-treated group, 0.33±0.58 in the 3 nM TAX-treated group, 1.33±0.58 in the 6 nM BSNtreated group, and 0 in the 6 nM DSN-and TAX-treated groups). This was not surprising as BSNs greatly reduced the number of CFU-GEMMs, which was very low. When cells were treated with 10 nM DSNs or TAX, no BFU-E or CFU-GEMM colony was observed (data not shown). Taken together, DSNs greatly reduced the myelosuppression toxicity of TAX by promoting proliferation and differentiation of the bone marrow progenitor cells.
Discussion
Although docetaxel (TAX) is one of the most widely used antitumor drugs in clinical chemotherapy to treat several solid cancers, the severe side effects, such as myelosuppression, neutropenia, anemia, and hypersensitivity reaction, and its serious dose-limiting toxicity limit its applications in cancer therapy. [9] [10] [11] To improve its side effects while still keep its antitumor activity, new formulations are needed to achieve better clinical applications. In recent decades, nanoscience and nanotechnology has been used in the biomedical field, and they have greatly promoted the development of pharmacy.
Until now, many nanoformulations of docetaxel have been developed. 16, 18, 24 Compared with other nanoformulations, solid lipid nanoparticles exhibit many advantages, including easier preparation, better stability, and component material safety. 16, 29, 30, 39 The authors have developed novel DSNs using a very simple and convenient method to systemically analyze the toxicity. 29 These newly developed DSNs can increase the maximum tolerated dose of docetaxel and reduce its inherent toxicity. Previous studies have shown that docetaxel suppresses the growth of breast cancer MCF-7 cells. 7, 8 In this study, MCF-7 breast cancer cells were used to evaluate the tumor suppression activity and myelosuppression toxicity of DSNs. Compared with TAX, DSNs showed lower toxicity at a low dose (eg, 2 nM in 72 hours) in culture cells. While DSNs still keep the antitumor activity of docetaxel, such as inhibiting cell growth, arresting cell cycle progression in the G2/M stage, and inducing apoptosis, it can induce more apoptosis when treated for 24 hours at the 5 nM dose. The in vivo experiments in tumor-bearing nude mice also proved that DSNs and TAX have almost the same antitumor effect.
While the antitumor mechanisms of TAX have been studied before, it is not yet known whether the nano-based DSNs work the same way. To understand the intrinsic mechanisms of DSNs, systemic analysis was performed using microarray to detect gene transcription and then verified with qPCR and immunoblotting. DSN treatment can cause the up-and downregulation of genes similar to TAX, as seen by the large group of common genes shared by both TAX and DSNs.
Myelosuppression is the main side effect of TAX in clinical application; DSNs significantly reduced myelosuppression toxicity compared with TAX when tested in beagle dogs. 
Conclusion
The DSNs reduced cytotoxicity, arrested cell cycle progression in the G2/M stage, and induced more apoptosis in MCF-7 cells at a low dose compared with TAX. DSNs and TAX have almost equal antitumor efficacy in tumor-bearing mice. Genes regulated by DSNs and TAX have functions in cell proliferation, apoptosis, and cell cycle control. DSN-and TAX-upregulated or downregulated genes mostly overlap; these genes have functions in DNA replication, DNA damage response, the cytoskeleton, and the cell cycle. Lastly, DSNs greatly reduce myelosuppression toxicity by recovering the proliferation and differentiation of bone marrow progenitor cells. The hematopoietic recovery effect of docetaxel-loaded solid lipid nanoparticles. Notes: Bone marrow cells from mice were incubated with blank solid lipid nanoparticles, docetaxel-loaded solid lipid nanoparticles, or Taxotere ® at 3 nM or 6 nM for 9 days in methylcellulose-based media. Mock-treated cells were used as the control. Optical photos show the microscopic colonies that formed in a 24-well plate (A). colonies of colony forming units that generate granulocytes and macrophages (B), burst-forming units that generate erythroids (C), and colony forming units that generate granulocytes, erythroids, macrophages, and megakaryocytes (D) were counted using an inverted microscope. The data are presented as mean ± standard error from three experiments. *P0.05. **P0.01. Abbreviations: BFU-e, burst-forming units that generate erythroids; BsN, blank solid lipid nanoparticle; ctrl, control; cFU-geMM, colony forming units that generate granulocytes, erythroids, macrophages, and megakaryocytes; cFU-gM, colony forming units that generate granulocytes and macrophages; DsN, docetaxel-loaded solid lipid nanoparticle; TaX, Taxotere. 
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Supplementary materials
Figure S1
The morphology of docetaxel-loaded solid lipid nanoparticles observed by transmission electron microscopy. 
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